Technology area: Biotechnology & Pharmaceuticals
10 pending office actions • 5 art units • 9 examiners • 0 of 10 (0%) have an AI response strategy ready • 8 patents granted in the last 365 days
Autolus Limited has 11 pending office actions in Biotechnology & Pharmaceuticals. The matters span 10 examiners and 5 art units, indicating a substantial prosecution footprint distributed across several technical examination settings.
WESTON, ALYSSA G is the busiest examiner, with 2 pending matters. That allocation is the largest individual examiner assignment in the profile, but the record remains broadly distributed among the other examiners.
The presence of 5 art units supports separate review of claim scope, cited art, and response history by technical grouping. Counsel should coordinate recurring biotechnology positions where appropriate, while preserving examiner-specific arguments and amendments for each pending matter.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (10%) |
| §103 only | 3 (30%) |
| §102 only | 1 (10%) |
| §112 only | 1 (10%) |
| Double-patenting + other | 2 (20%) |
| Multi-statute (no §101) | 2 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WESTON, ALYSSA G | 2 | 59.5% | +49.0% |
| WEIDNER, ADAM M | 1 | 63.7% | +33.6% |
| BURKHART, MICHAEL D | 1 | 62.4% | +11.8% |
| MONTANARI, DAVID A | 1 | 64.8% | +49.0% |
| MARVICH, MARIA | 1 | 55.0% | +28.0% |
| SHIN, DANA H | 1 | 26.9% | +26.9% |
| DHAR, MATASHA | 1 | 43.5% | +44.8% |
| RAHMAN, MASUDUR | 1 | 72.9% | +31.7% |
| GONZALES, JOSEPHINE MARIA | 1 | 28.8% | +34.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18515458 | CHIMERIC ANTIGEN RECEPTOR | BURKHART, MICHAEL D | 42d overdue |
| 18279568 | GENERATION OF T-CELLS BY DIRECT REPROGRAMMING FROM FIBROBLASTS AND MSC | MONTANARI, DAVID A | — |
| 17924345 | METHOD | SHIN, DANA H | — |
| 17915689 | METHOD FOR SELECTING CELLS EXPRESSING A NUCLEIC ACID OF INTEREST | WESTON, ALYSSA G | — |
| 16470965 | TRANSCRIPTION SYSTEM | GONZALES, JOSEPHINE MARIA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18515458 | CHIMERIC ANTIGEN RECEPTOR | BURKHART, MICHAEL D | 42d overdue |
| 17601684 | CELL | RAHMAN, MASUDUR | 32d overdue |
| 18525271 | CELL EXPRESSING A CAR AND A TRANSCRIPTION FACTOR AND ITS USE | WEIDNER, ADAM M | — |
| 18279568 | GENERATION OF T-CELLS BY DIRECT REPROGRAMMING FROM FIBROBLASTS AND MSC | MONTANARI, DAVID A | — |
| 18160032 | Retroviral And Lentiviral Vectors | MARVICH, MARIA | — |
| 17924345 | METHOD | SHIN, DANA H | — |
| 17915689 | METHOD FOR SELECTING CELLS EXPRESSING A NUCLEIC ACID OF INTEREST | WESTON, ALYSSA G | — |
| 17915637 | CELL | DHAR, MATASHA | — |
| Art Unit | Apps |
|---|---|
| 1633 | 3 |
| 1632 | 2 |
| 1631 | 2 |
| 1638 | 1 |
| 1635 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18525271 | CELL EXPRESSING A CAR AND A TRANSCRIPTION FACTOR AND ITS USE | WEIDNER, ADAM M | — | §103 | Non-Final OA | — | Pending | Nov 30, 2023 |
| 18515458 | CHIMERIC ANTIGEN RECEPTOR | BURKHART, MICHAEL D | 1638 | §103§112 | Final Rejection | 42d overdue | Pending | Nov 21, 2023 |
| 18279568 | GENERATION OF T-CELLS BY DIRECT REPROGRAMMING FROM FIBROBLASTS AND MSC | MONTANARI, DAVID A | 1632 | §101§102§103 | Non-Final OA | — | Pending | Aug 30, 2023 |
| 18160032 | Retroviral And Lentiviral Vectors | MARVICH, MARIA | 1631 | §102§112DP | Non-Final OA | — | Pending | Jan 26, 2023 |
| 17924345 | METHOD | SHIN, DANA H | 1635 | §103Other | Final Rejection | — | Pending | Nov 09, 2022 |
| 17915689 | METHOD FOR SELECTING CELLS EXPRESSING A NUCLEIC ACID OF INTEREST | WESTON, ALYSSA G | 1633 | §102§103 | Non-Final OA | — | Pending | Sep 29, 2022 |
| 17915637 | CELL | DHAR, MATASHA | 1632 | §103 | Non-Final OA | — | Pending | Sep 29, 2022 |
| 17601684 | CELL | RAHMAN, MASUDUR | 1633 | §112 | Final Rejection | 32d overdue | Pending | Oct 05, 2021 |
| 17436673 | COMPOSITIONS AND METHODS COMPRISING ENGINEERED CHIMERIC ANTIGEN RECEPTOR AND MODULATOR OF CAR | WESTON, ALYSSA G | 1633 | §102 | Final Rejection | — | Pending | Sep 07, 2021 |
| 16470965 | TRANSCRIPTION SYSTEM | GONZALES, JOSEPHINE MARIA | 1631 | §103DP | Non-Final OA | — | Pending | Jun 18, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAutolus Limited has 10 pending office actions as of October 2026, spread across 5 art units and 9 examiners.
Alyssa G Weston has the most, with 2 of Autolus Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
